Profile data is unavailable for this security.
About the company
Shuttle Pharmaceuticals Holdings, Inc. is a discovery and development stage specialty pharmaceutical company. The Company is focused on improving the outcomes of cancer patients treated with radiation therapy (RT). It is developing a pipeline of products designed to address cancer therapies as well as to extend to the new applications of radiation therapy. Its product candidates include Ropidoxuridine (IPdR), Ropidoxuridine and Tipracil (IPdR/TPI), SP-1-161, SP-2-225, and SP-1-303. Ropidoxuridine (IPdR) is its lead candidate radiation sensitizer for use in combination with RT to treat brain tumors (glioblastoma) and sarcomas. Ropidoxuridine and Tipracil (IPdR/TPI) is undergoing preclinical development for use as a radiation sensitizer for rectal cancers. SP-1-161 is a pre-clinical candidate lead histone deacetylase (HDAC) inhibitor, a radiation sensitizing candidate product. SP-2-225 is a pre-clinical class II b selective HDAC inhibitor that affects histone deacetylase HDAC6.
- Revenue in USD (TTM)0.00
- Net income in USD-7.35m
- Incorporated2018
- Employees8.00
- LocationShuttle Pharmaceuticals Holdings Inc401 Professional Drive, Suite 260GAITHERSBURG 20879United StatesUSA
- Phone+1 (240) 403-4212
- Fax+1 (845) 818-3588
- Websitehttps://shuttlepharma.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Kazia Therapeutics Ltd (ADR) | 14.85k | -13.47m | 7.43m | 12.00 | -- | 0.7173 | -- | 500.20 | -0.817 | -0.817 | 0.0008 | 0.3478 | 0.0007 | -- | 73.97 | -- | -63.98 | -46.35 | -82.39 | -54.75 | -- | -- | -90,714.45 | -497.17 | -- | -- | 0.1297 | -- | 979.43 | -28.31 | 18.19 | -- | -- | -- |
| Oragenics Inc | 20.63k | -20.26m | 7.48m | 5.00 | -- | 7.25 | -- | 362.71 | -7.98 | -7.98 | 0.0079 | 0.5859 | 0.0026 | -- | -- | 4,126.00 | -258.71 | -97.60 | -312.34 | -106.24 | -- | -- | -98,214.93 | -36,169.75 | -- | -- | 0.0461 | -- | -71.37 | -- | -44.56 | -- | 51.64 | -- |
| Integrated BioPharma, Inc. | 50.57m | -116.00k | 7.52m | 141.00 | -- | 0.3979 | 35.49 | 0.1488 | -0.0041 | -0.0041 | 1.67 | 0.6283 | 1.88 | 4.45 | 10.76 | 358,617.00 | -0.431 | 15.51 | -0.5698 | 27.94 | 7.09 | 12.09 | -0.2294 | 6.44 | 1.02 | -9.00 | 0.001 | -- | -9.91 | 3.00 | -101.35 | -- | -14.03 | -- |
| Cadrenal Therapeutics Inc | -100.00bn | -100.00bn | 7.53m | 3.00 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- |
| Bon Natural Life Ltd | 29.52m | 4.60m | 7.70m | 96.00 | 0.3888 | 0.0642 | 1.40 | 0.2609 | 4.99 | 4.99 | 32.10 | 30.23 | 0.7045 | 15.27 | 5.19 | 307,524.60 | 10.86 | 14.04 | 13.69 | 20.68 | 29.94 | 30.00 | 15.42 | 17.62 | 2.41 | 30.54 | 0.0955 | 0.00 | -1.29 | 22.32 | -26.32 | 83.09 | -6.70 | -- |
| Notable Labs Ltd | 311.00k | -12.39m | 7.71m | 16.00 | -- | 0.6679 | -- | 24.79 | -2.31 | -2.31 | 0.0622 | 1.28 | 0.0142 | -- | -- | 19,437.50 | -56.70 | -52.02 | -74.10 | -62.09 | 37.30 | 60.19 | -3,984.24 | -3,636.93 | -- | -- | 0.0271 | -- | -52.89 | -11.93 | 65.13 | -- | -50.69 | -- |
| National Graphite Corp | 0.00 | -1.97m | 7.72m | 0.00 | -- | -- | -- | -- | -0.0221 | -0.0221 | 0.00 | -0.0193 | 0.00 | -- | -- | -- | -11,014.44 | -212.13 | -- | -6,295.18 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -1,432.70 | -- | -- | -- |
| Molecular Templates Inc | 31.76m | -18.40m | 7.77m | 62.00 | -- | 1.08 | -- | 0.2446 | -4.36 | -4.36 | 5.98 | 1.09 | 0.6014 | -- | 19.55 | 512,306.40 | -34.83 | -51.78 | -54.80 | -73.14 | -- | -- | -57.92 | -228.33 | -- | -52.11 | 0.00 | -- | 190.10 | 33.96 | 91.24 | -- | -48.87 | -- |
| Twinlab Consolidated Holdings Inc | 12.65m | -9.55m | 7.77m | 17.00 | -- | -- | -- | 0.6146 | -0.0369 | -0.0502 | 0.0488 | -0.5447 | 1.01 | 1.49 | 7.30 | 743,941.20 | -76.13 | -60.53 | -- | -- | 34.59 | 21.36 | -75.51 | -37.72 | 0.0094 | -0.0108 | -- | -- | -20.87 | -28.58 | -20.28 | -- | -- | -- |
| Shuttle Pharmaceuticals Holdings Inc | 0.00 | -7.35m | 7.81m | 8.00 | -- | 2.83 | -- | -- | -0.4739 | -0.4739 | 0.00 | 0.1642 | 0.00 | -- | -- | 0.00 | -96.75 | -- | -119.37 | -- | -- | -- | -- | -- | -- | -5.28 | 0.2542 | -- | -- | -- | -112.71 | -- | -- | -- |
| BioRestorative Therapies Inc | 145.80k | -14.42m | 7.85m | 11.00 | -- | 0.4734 | -- | 53.86 | -3.54 | -3.54 | 0.0346 | 2.45 | 0.01 | -- | 8.26 | 13,254.55 | -99.26 | -199.86 | -104.68 | -334.04 | -- | -- | -9,887.16 | -19,887.03 | -- | -- | 0.00 | -- | 21.70 | 5.61 | 22.06 | -- | 67.77 | -- |
| Glucose Health Inc | 1.11m | -456.46k | 7.94m | 2.00 | -- | 8.38 | -- | 7.14 | -0.033 | -0.033 | 0.0803 | 0.0561 | -- | -- | -- | -- | -- | -86.94 | -- | -153.95 | 47.19 | 40.68 | -31.99 | -56.93 | 313.11 | -- | 0.00 | -- | 98.39 | 24.94 | 16.87 | -- | -- | -- |
| Lotus Pharmaceuticals Inc | 70.79m | 1.72m | 8.08m | 233.00 | 0.0542 | 0.0008 | 2.09 | 0.1142 | 0.0553 | 0.0553 | 2.56 | 3.58 | 0.6321 | 37.27 | 17.85 | 303,836.90 | 1.55 | 22.84 | 1.71 | 26.40 | 35.10 | 41.62 | 2.45 | 19.93 | 0.4428 | 30.80 | 0.0516 | 0.00 | 28.71 | 31.70 | -12.22 | 51.11 | 70.48 | -- |
| Chromocell Therapeutics Corp | 0.00 | -8.98m | 8.19m | 4.00 | -- | 7.25 | -- | -- | -1.66 | -1.66 | 0.00 | 0.196 | 0.00 | -- | -- | 0.00 | -440.01 | -- | -- | -- | -- | -- | -- | -- | -- | -7.20 | 0.00 | -- | -- | -- | -200.20 | -- | -- | -- |
Data as of Jun 10 2024. Currency figures normalised to Shuttle Pharmaceuticals Holdings Inc's reporting currency: US Dollar USD
1.70%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Ayrton Capital LLCas of 30 Sep 2023 | 220.43k | 1.31% |
| Geode Capital Management LLCas of 31 Mar 2024 | 36.96k | 0.22% |
| Renaissance Technologies LLCas of 31 Mar 2024 | 16.50k | 0.10% |
| Virtu Americas LLCas of 31 Mar 2024 | 10.48k | 0.06% |
| UBS Securities LLCas of 31 Mar 2024 | 1.12k | 0.01% |
| Desjardins Securities, Inc.as of 31 Mar 2024 | 500.00 | 0.00% |
| Tower Research Capital LLCas of 31 Mar 2024 | 251.00 | 0.00% |
| Wells Fargo Bank, NA (Private Banking)as of 31 Mar 2024 | 54.00 | 0.00% |
| StoneX Group, Inc. (Investment Management)as of 31 Mar 2024 | 0.00 | 0.00% |
More ▼
Data from 30 Sep 2023 - 31 Mar 2024Source: FactSet Research Systems Inc.
